Articles related to SCHIZOPHRENIA

A J Clin Psychiatry commentary proposes a risk-benefit matrix favoring empiric catatonia treatment when diagnostic uncertainty exists, citing the syndrome’s high morbidity and the effectiveness of available interventions.

The FDA approved a supplemental NDA adding randomized withdrawal trial data to the lumateperone label, supporting its role in long-term maintenance and relapse prevention in adults with schizophrenia.

A network meta-analysis of 24 antipsychotics across 78,193 patients with schizophrenia identified clozapine, amisulpride, olanzapine, and risperidone as most effective, with small-to-medium efficacy differences and notable variation in tolerability profiles.

The new chemical entity is an atypical antipsychotic and the active metabolite of iloperidone (Fanapt). Its ability to cross the blood-brain barrier likely contributes to iloperidone’s clinical effects.

“For most patients in the early stages of schizophrenia, symptomatic remission can be achieved using a simple treatment algorithm comprising the sequential administration of amisulpride and clozapine.” — Leucht et al, J Clin Psychiatry 2026

“Evenamide has the potential to treat the symptoms of schizophrenia more broadly, addressing also those poorly managed by the currently available antipsychotics.” — Ravi Anand, MD, Therapeutic Advances in Psychopharmacology